NCT04220203 2025-06-26Treatment Protocol of Tucatinib With Capecitabine and Trastuzumab in Patients With Unresectable Previously Treated HER2+ Breast CancerSeagen Inc.Approved for marketing
NCT04395508 2022-07-05An Expanded Access Study to Provide at Home Subcutaneous Administration of Pertuzumab and Trastuzumab Fixed-Dose Combination (PH FDC SC) for Patients With HER2-Positive Breast Cancer During the COVID-19 PandemicGenentech, Inc.Approved for marketing